News
Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...
Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...
Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Zacks.com on MSN2d
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...
Pharmaceutical stocks fell across Asian markets after U.S. President Trump said he plans to impose a "major" tariff on all pharmaceutical imports.
Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no ...
Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...
BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...
(RTTNews) - Pacira BioSciences Inc. (PCRX) announced that it has settled its litigations with Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals ...
"China's biotechnology sector thrives on a dual engine — Beijing's constellation of famous medical universities training ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback